Show simple item record

O-5. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study

dc.contributor.authorVogel, A.
dc.contributor.authorChan, S.
dc.contributor.authorFuruse, J.
dc.contributor.authorTak, W.
dc.contributor.authorMasi, G.
dc.contributor.authorVarela Calvo, María 
dc.contributor.authorKim, J.
dc.contributor.authorTanasanvimon, S.
dc.contributor.authorReig, M.
dc.contributor.authorDayyani, F.
dc.contributor.authorMakowsky, M.
dc.contributor.authorMarcovitz, M.
dc.contributor.authorNegro, A.
dc.contributor.authorAbou Alfa, G.
dc.date.accessioned2023-03-15T10:33:39Z
dc.date.available2023-03-15T10:33:39Z
dc.date.issued2022
dc.identifier.issn0923-7534
dc.identifier.issn1569-8041
dc.identifier.urihttp://hdl.handle.net/10651/66955
dc.descriptionResumen presentado al World Congress on Gastrointestinal Cancer (24th. 2022. Barcelona)
dc.description.sponsorshipAstraZeneca
dc.format.extentp. S380-S381
dc.language.isoeng
dc.relation.ispartofAnnals of oncology
dc.rights© 2022 European Society for Medical Oncology. Published by Elsevier Ltd.
dc.sourceWOS:000823826500369
dc.titleO-5. Outcomes by baseline liver function in patients with unresectable hepatocellular carcinoma treated with tremelimumab and durvalumab in the phase 3 HIMALAYA study
dc.typeconference outputspa
dc.identifier.doi10.1016/j.annonc.2022.04.446
dc.relation.publisherversionhttp://dx.doi.org/10.1016/j.annonc.2022.04.446


Files in this item

FilesSizeFormatView

There are no files associated with this item.

This item appears in the following Collection(s)

Show simple item record